We’re reading about FDA inspections, Lilly insulin trial results

Amid the ongoing struggle of federal regulators to conduct drug manufacturing inspections post-COVID-19, concerns are raised about risks of contamination in drugs used by Americans. A significant number of pharmaceutical firms are overdue for safety inspections, posing potential quality issues. In other news, Eli Lilly’s once-weekly insulin is showing promise in pivotal studies, competing with a Novo Nordisk product. With preliminary data showing comparable results to daily insulin injections, the experimental insulin is advancing in Phase 3 trials. Overall, the pharmaceutical industry continues to face challenges in ensuring drug safety and quality amid the ongoing pandemic.

Source link